Diligence memo · auto-generated · as of July 2, 2026
ThelioPulse, Inc.
ThelioPulse, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
ThelioPulse, Inc. operates in Biotechnology, based in LOS ANGELES.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
ThelioPulse, Inc. has raised $5.3M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.1M on 2012-02-08.
Most recent recorded round closed around 2013-07-17.
Valuation (modeled)modeled
Provath models ThelioPulse, Inc. at approximately $8.0M (range $240K–$43M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.05× the median modeled value of Series A Biotechnology companies in 2013–2015 (111 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 17 months.
Last raise 13.0 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 23.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 45% of Biotechnology peers (4293 compared).
Modeled value ranks above 15% of those peers.
Closest niche peers: Dnanexus, Inc., Foresight Biotherapeutics, Inc., AuraSense Therapeutics, LLC, Zyomyx Inc, Champions Oncology, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.